Free Newsletter
VC: Immatics gains $52.6M in second round
Immatics gains $52.6M in second round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Immatics
|
$52.6M
|
Wellington Partners and 3i |
Much of that will be used to fund two clinical trials for the company's cancer therapies. |
|
CoDa Therapeutics
|
$10M
|
Domain Associates and GBS Ventures |
The money has been earmarked for clinical trials of its tissue repair program. |
|
REGiMMUNE
|
$4.2M
|
NIF SMBC Ventures |
Proceeds from the financing will be used to further the preclinical development of REGiMMUNE's first two product candidates, RGI-2001 and RGI-1001. |
SHARE
WITH: